'Defanged' HIV used to deliver gene therapy

Researchers are having success using a "defanged" version of HIV to deliver gene therapy to children suffering from genetic diseases, a development that could improve other such care.

The Wall Street Journal: Defanged HIV Shows Promise In Gene Therapy 
Six children with rare genetic diseases were successfully treated using gene therapy that was delivered with a modified form of the AIDS virus, researchers said Thursday. HIV, which causes AIDS, is proving a boon to gene therapy because the ability to infect cells that makes the virus so dangerous has also rendered it an efficient agent for delivering replacement genes into a patient (Winslow, 7/11).

Los Angeles Times: Gene Therapy Using HIV Helps Children With Fatal Diseases, Study Says
Italian researchers have used a defanged version of HIV to replace faulty genes -- and eliminate devastating symptoms -- in children suffering two rare and fatal genetic diseases. Improved gene therapy techniques prevented the onset of metachromatic leukodystrophy in three young children and halted the progression of Wiskott-Aldrich syndrome in three others (Pandika, 7/11).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered tool predicts gene activity in cancer cells from biopsy images